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Abstract (200 words): 24 
Overactive Bladder (OAB) is an idiopathic condition, characterized by urgency, 25 
urinary frequency and urgency incontinence, in the absence of routinely traceable 26 
urinary infection.  We have described microscopic pyuria (≥10 wbc μl-1) in patients 27 
suffering from the worst symptoms.  It is established that inflammation is associated 28 
with increased ATP release from epithelial cells, and extracellular ATP originating 29 
from the urothelium following increased hydrostatic pressure, is a mediator of 30 
bladder sensation.  Here, using bladder-biopsy samples, we have investigated 31 
urothelial ATP signaling in OAB patients with microscopic pyuria. 32 
Basal, but not stretch-evoked, release of ATP was significantly greater from 33 
urothelium of OAB patients with pyuria than from non-OAB patients or OAB patients 34 
without pyuria (<10 wbc μl-1).  Basal ATP release from urothelium of OAB patients 35 
with pyuria was inhibited by the P2 receptor antagonist suramin and abolished by 36 
the hemichannel blocker carbenoxolone, which differed from stretch-activated ATP 37 
release. Altered P2 receptor expression was evident in urothelium from pyuric OAB 38 
patients.  Furthermore, intracellular bacteria were visualized in shed urothelial cells 39 
from ~80% of OAB patients with pyuria. 40 
 These data suggest that increased ATP release from the urothelium, involving 41 
bacterial colonization, may play a role in the heightened symptoms associated with 42 
pyuric OAB patients. 43 
 44 
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Introduction: 46 
Overactive bladder syndrome (OAB) is an idiopathic condition where the bladder 47 
detrusor urinae muscle spontaneously contracts before the bladder is full.  In the 48 
USA, it is ranked in the top 10 of common chronic conditions, competing with both 49 
diabetes and depression, with a reported prevalence of up to 31-42% in the adult 50 
population (2).   51 
OAB is currently characterized by symptoms of urgency, with or without 52 
urgency incontinence, with increased frequency, and nocturia, and in some cases 53 
pain, in the absence of urinary tract infection (UTI) or other defined underlying 54 
pathology (54). The exclusion of infection is determined by failure to isolate ≥105 55 
colony forming units (CFU)/ml of a single species of bacteria from culture of a 56 
midstream urine (MSU) specimen (23) and negative leukocyte esterase and/or 57 
nitrate urinalysis by dipstick (25).  Controversy exists as to whether current methods 58 
used to determine UTI are fully accurate (28).  It has been established that the 59 
bacterial threshold of ≥105 CFU/ml, in the presence of symptoms, is not identified in 60 
approximately 50% of UTI (31).  In addition, we have recently reported the low 61 
sensitivity and specificity of routine urinary dipstick tests (20, 51).  Interestingly, in 62 
recent studies where the threshold has been reduced to ≥102 CFU/ml, bacterial 63 
cystitis has been identified in approximately one third of patients with refractory 64 
OAB, suggesting bacteria may play a significant role in the aetiology of OAB, in at 65 
least a subset of patients with OAB (22, 37, 49).  It is generally accepted, that the 66 
best indicator of UTI is the detection of ≥10 white blood cells (wbc) in 1 µl of fresh, 67 
un-spun, urine examined using a haemocytometer (16, 44); however nowadays this 68 
is not normal clinical practice.  Using this methodology, we have identified a low-69 
grade inflammatory response (pyuria with ≥10 wbc µl-1) in 10-35% of MSU 70 
specimens from patients with OAB (i.e. symptoms of urgency, with or without 71 
urgency incontinence, with frequency and nocturia, in the absence of UTI) (45, and 72 
new data not shown).  Interestingly, our observation is that these patients showed 73 
the worst symptoms of frequency.  Most apposite to this finding is that persistent 74 
inflammation, caused by infection and thereby accompanied by pyuria, is associated 75 
with increased nucleotide (primarily adenosine 5’-triphosphate [ATP]) release from 76 
epithelial cells and nucleotide-activated P2 receptor signaling (4, 5, 36, 55). 77 
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Extracellular nucleotide signaling via P2 receptor activation is important in 78 
the regulation of bladder function (3, 7, 8).  Bladder stretch, during filling, induces a 79 
cytosolic Ca2+ increase via multiple proposed pathways (9) to promote release of ATP 80 
through conductive or vesicular pathways (46), and probably other nucleotides from 81 
superficial urothelium.  Once released, nucleotides bind to P2 receptors on 82 
suburothelial sensory afferents (P2X2, 3 and/or 2/3 subtypes) to trigger nerve 83 
activation and the sensation of bladder fullness and the urge to urinate (52).  Given 84 
the rapid breakdown of extracellular nucleotides by nucleotidases, this route should 85 
involve intermediate signaling steps involving activation of P2 receptors on other 86 
urothelial cells to release additional nucleotides to act in an autocrine/paracrine 87 
manner (17, 19, 48, 58). Nucleotide signaling in human urothelium is enhanced in 88 
interstitial cystitis (IC) in humans and felines (17, 58), a condition symptomatically 89 
similar to OAB yet with the presence of pain and an inflammatory aetiology.  In IC, 90 
stretch-activated ATP release is significantly increased, P2R expression profiles are 91 
altered in the urothelium, and ATP breakdown is purportedly decreased (15, 58).  92 
Interestingly, studies on humans with acute cystitis/urinary infection demonstrate 93 
that uropathogenic E. coli (UPEC) can thrive in the urothelium as intracellular 94 
bacterial colonies resisting host immunity (29), that should be accompanied by 95 
increased nucleotide release from epithelial cells (see paragraph above). 96 
We hypothesize that in a subset of OAB patients (i.e. those with pyuria ≥10 97 
wbc μl-1) there is increased release of ATP, and other nucleotides, from the 98 
urothelium caused by low-grade inflammation, which ultimately results in increased 99 
sensory nerve excitation and the enhanced symptoms of OAB.  Furthermore, in 100 
these patients the low-grade inflammation is associated with intracellular bacteria 101 
colonization of the urothelium.  Here we investigated our hypothesis using human 102 
bladder urothelium obtained using flexible cystoscopy. 103 
 104 
Methods: 105 
Reagents.  Chemical reagents were purchased from Sigma-Aldrich (Poole, UK); with 106 
the exception of suramin obtained from Bayer AG (Leverkusen, Germany) and DAPI-107 
containing microscope slide mountant obtained from Vector Labs (Peterborough, 108 
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UK).  HPLC column and solid phase extraction cartridges were obtained from 109 
Phenomenex (Macclesfield, UK).  110 
 111 
Human tissue and urine samples. All procedures were performed with consent and 112 
approval from the Moorfields and Whittington Hospitals Research Ethics Committee 113 
(London, UK) and the NHS Research Authority South East Coast (Kent).  Informed 114 
written consent was obtained from volunteers involved in the study.  Bladder 115 
biopsies and urine samples were obtained from either the Whittington Hospital 116 
Campus, University College London or Medway Maritime Hospital.  Bladder biopsies 117 
were obtained using a flexible cystoscope under local (or rarely general) anaesthesia.  118 
A catheter specimen of urine (CSU) was obtained from female patients and a MSU 119 
from male patients and non-OAB controls.  Patients with idiopathic OAB were 120 
recruited from Incontinence Clinics and non-OAB controls were recruited from the 121 
Haematuria Clinic.  The inclusion criteria for OAB, reconfirmed at the time of sample 122 
collection, were adults aged ≥18 years of either sex with frequency ≥8 per day, 123 
urgency with or without urgency incontinence, and the absence of a UTI or severe 124 
concomitant urinary tract pathology (e.g. chronic obstruction, catheterisation, 125 
neurological disease, prior radiotherapy, anatomical defects, implanted devices, 126 
pregnancy, bleeding disorders, and/or anticoagulant therapy).  All urine samples 127 
obtained were sent for conventional urinalysis and bacteria culture at the time of 128 
collection, if a UTI was subsequently identified the sample was retrospectively 129 
removed from the study.  The inclusion criteria for non-OAB were a single historical 130 
episode of microscopic haematuria with no underlying pathology.  All OAB and non-131 
OAB patients were additionally investigated for pyuria by trained clinicians as 132 
previously described (20); significant pyuria was taken as of ≥10 wbc μl-1 of fresh un-133 
spun urine.  Thus the following experimental groups were used in this investigation: 134 
i) non-OAB controls, ii) OAB patients without pyuria, that is patients with no wbc or 135 
with <10 wbc μl-1, and iii) OAB patients with pyuria, that is patients with ≥10 wbc μl-136 
1.  Urine was either stored on ice and processed within 1 h (for microscopy) or 137 
immediately snap-frozen and kept at -80°C until the time of processing (for HPLC).  138 
Bladder biopsies were either immediately transported to the laboratory in ice-cold 139 
sterile saline and processed within 1 h of collection or placed in 10% formalin for 48 140 
 6
h prior to histological scrutiny.  141 
 142 
Bioiopsy histology. Following 48 h in 10% formalin, biopsy tissue was dehydrated 143 
with alcohol and xylene in a vacuum infiltration-processing machine for 12 h.  The 144 
tissue was then impregnated with paraffin wax.  A microtome (Microm HM355S; 145 
Thermo Fisher Scientific, Loughborough, UK) was used to cut sections of 6 µm 146 
thickness.  Slices were placed on a glass slide then dried at 60°C for 10 min.  The 147 
sections were then stained with H&E to evaluate the morphological characteristics of 148 
the tissue. A Leica DM4000B upright light microscope (Wetlar, Germany) was used to 149 
image the sections. 150 
 151 
Biopsy ATP release.  A Luciferin Luciferase ATP Bioluminiscence Assay Kit was used to 152 
quantify ATP release from intact, live, bladder urothelium according to the 153 
manufacturer’s protocol.  In brief, the urothelial cell layer was manually isolated 154 
from the underlying tissue of the bladder biopsy using fine forceps, scalpel and a 155 
dissection microscope (final wet tissue weight being 3.4±0.7 mg [n=33]).  Two 156 
working solutions containing the luciferin luciferase reagents were made up, one in 157 
PBS (0.1 M; Solution-A) and one with distilled water (Solution-B).  The intact 158 
urothelial cell layer was then incubated for 1 h in Solution-A (100μl) at 37°Cin a 96-159 
well plate (Nunc, Roskilde, Denmark).  Basal readings of luminescence were taken 160 
after 1 h incubation with the tissue still immersed in Solution-A.   Stimulated 161 
readings of luminescence (i.e. stretch-evoked ATP release) were taken following the 162 
addition of Solution-B (100μl) for 1 min.  Where stated, stimulated readings of 163 
luminescence were taken over a period of 15 min with 3 min interval recordings to 164 
observe degradation of ATP with time. Two ATP standard curves, one in Solution-A 165 
(100 μl volume), and the other in Solution-A and Solution-B (50:50, 200 μl volume), 166 
in combination with blank wells, were prepared alongside each given experiment 167 
with concentrations ranging from 10-10 to 10-7 M.  ATP-evoked luminescence was 168 
quantified using a luminometer (Synergy 2, BioTek, Winooski, USA).  ATP 169 
concentration from samples was calculated from the ATP standards using linear 170 
regression analysis.  All data were normalised as nM ATP per 5 mg of wet tissue, and 171 
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stimulated readings presented following the subtraction of basal readings. In 172 
experiments investigating the effect of drugs, the same protocol was followed, 173 
allowing a minimum of 5 min for the drugs to take effect before luminescence was 174 
read. Parallel standard curves were also run in the presence of drugs to investigate 175 
any possible interactions with the luciferin luciferase reaction. 176 
 177 
Biopsy vesicle staining.  Following immediate transport to the laboratory in ice-cold 178 
sterile saline, biopsy tissue was placed in PBS (0.1 M) and incubated for 1 h at 37 °C 179 
to create resting conditions, or, to imitate stretch conditions (i.e. bladder filling), 180 
biopsy tissue was then incubated in hypotonic PBS (0.05 M) for 1 min.  Both the 181 
resting and stretch biopsy tissues were immediately transferred to PFA (4%) for 48 h, 182 
before being wax-embedded and sectioned (as above: Biopsy histology).  The tissue 183 
sections were permeated with a 0.1% Triton X100 solution and incubated with 184 
quinacrine (100 µM) for 30 min before being washed with PBS (0.1 M). Sections 185 
were mounted with DAPI-containing mountant, and visualised under an inverted 186 
confocal microscope using the x63 oil immersion objective (Leica SP5; Wetzlar, 187 
Germany).  Using ImageJ software, mean fluorescence intensity was measured in all 188 
images taken from quinacrine-labelled tissue. 189 
 190 
Biopsy RNA extraction and RT-PCR.  Following immediate transport to the laboratory, 191 
in cold sterile saline, the urothelial cell layer was manually isolated from the 192 
underlying tissue of the bladder biopsy using fine forceps, scalpel and a dissection 193 
microscope.  Intact urothelium was homogenised in Tri-reagent and then 194 
freeze/thawed in liquid nitrogen followed by chloroform extraction and ethanol 195 
precipitation.  Precipitated RNA was loaded onto Qiagen RNeasy columns (Qiagen, 196 
Crawley, UK) for DNase treatment and further purification.  RNA concentration was 197 
measured using a spectrometer, Nano N-1000 system (Nanodrop Technologies, 198 
Wilmington, USA). 199 
Total RNA (10 ng) from each sample was reverse transcribed in a 20 µl reaction 200 
volume using the One-step Quantitect Reverse Transcription Kit (Qiagen, Crawley, 201 
UK) according to manufacturer’s instructions.  Primers for P2 receptor subtypes were 202 
designed using Primer 3 Web-software (Whitehead Institute for Biomedical 203 
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Research, Cambridge, USA) and manufactured by Eurofins-MWG (Ebersberg, 204 
Germany) (see Appendix for primers and mRNA accession numbers used).  The real-205 
time PCR, based on SyBR green detection, (Qiagen, Crawley, UK) was performed 206 
using a Chromo-4 thermal cycler (Bio-Rad, Hemel Hempstead, UK) with 2 µl total 207 
RNA.  Using a standard curve, created by duplicate serial dilutions of standard DNA 208 
(target sequence of interest) over 12 logarithmic orders and the thermal cycler 209 
software the relative concentrations of the target amplicons were determined. In 210 
addition, the standard curve was used to verify the linearity of amplification of each 211 
transcript; r2>0.99 in all cases. The relative concentrations of target in each run were 212 
expressed as a ratio to the housekeeping gene, GAPDH. All PCR products were 213 
checked for specificity and purity from a melting curve profile created after each run 214 
by the thermal cycler software. Homology of the PCR products was further checked 215 
for size by agarose gel electrophoresis. 216 
 217 
Urine sediment immunofluorescence.   Fresh urine (50 μl; within 1 h of collection and 218 
stored on ice) was spun onto slides using a cytospin (Sandon Cytospin 4, York, UK) at 219 
800 rpm for 5 min.  The deposit was stained with acridine orange (0.5% in Gey’s 220 
solution) for 30 min; previously shown to fluoresce green in the presence of viable 221 
organism DNA after excitation by a laser at 436-490 nm (12, 32). In order to 222 
differentiate extracellular from intracellular bacteria, a crystal violet counter-stain 223 
(0.1% in 150 mM NaCl) was added to quench the fluorescence of extracellular 224 
microorganisms.  Images were acquired using an upright fluorescence microscope 225 
(Leica DM4000B, Wetlar, Germany), samples were excited at 488 nm and emitted 226 
light collected with a 505-550 nm band pass filter.  On those slides found to have 227 
cells containing bacteria, the deposit was fixed with PFA (4%) for 2 min, then further 228 
treated with anti-Uroplakin III (Santa Cruz Biotechnology Inc; Santa Cruz, USA) for 12 229 
h, a specific marker of urothelial cells (10).  Alexa 555 (Invitrogen, UK) was used as a 230 
secondary antibody and incubated for 2 h, after which the slides were mounted with 231 
DAPI-containing mountant. Images were acquired with a confocal microscope (Leica 232 
SP5; Wetlar, Germany) and Z-series processed using Volocity software (Improvision, 233 
Coventry, UK). Alexa-555 and DAPI were excited at 543 nm and 405 nm, and 234 
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emittedlight was collected using a 560 nm long-pass filter and 420 nm long pass 235 
filter, respectively. 236 
 237 
Urine nucleotide and nucleoside quantification. Urine, that had previously been 238 
immediately snap-frozen and kept at -80°C, was thawed and sterile filtered through 239 
a 0.22 µm membrane prior to HPLC analysis.  HPLC analysis was performed as 240 
previously described (11).  In brief, the samples were then subjected to a solid phase 241 
extraction cleaning procedure through Strata-X columns (30 mg/ml; Phenomenex, 242 
Macclesfield, UK).  Elution was achieved using 25 mM ethanolamine at pH 5.0 and 243 
30% methanol in ethanolamine (pH 5.0). A standard curve was prepared alongside 244 
each HPLC experiment consisting of ADP only.  Samples (100 μl) were injected into 245 
the column (Polar-RP 4 μm 80A 250x4.6 mm, Phenomenex, Macclesfield, UK) and a 246 
gradient profile of 2%-30% acetonitrile in phosphate buffer was run for 20 min, with 247 
an additional 15 min stabilisation period. Nucleotides and nucleosides were UV-248 
detected at 254 nm and areas measured with the Agilent software (Agilent 249 
Technologies, Wokingham, UK).  Areas were then adjusted to the SPE cartridge 250 
performance and compared against standard curves to obtain the final 251 
concentration.  Urinary creatinine levels were measured using a commercial test 252 
(R&D Systems, Abingdon, UK) as per manufacturer’s instructions to ensure data 253 
were comparable.  254 
 255 
Statistical analysis.  All numerical data were assessed for normality using the 256 
Kolmogorov-Smirnov test. Significance level was evaluated by two-tailed paired and 257 
unpaired t-tests, parametric and non-parametric one-way ANOVA with appropriate 258 
post-hoc tests. P values less than 0.05 were considered statistically significant.  All 259 
data presented as mean±SEM, and n equals number of patients or samples. 260 
 261 
262 
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Results: 263 
Bladder biopsies obtained from patients using flexible cystoscopy have full-thickness 264 
intact urothelium. H&E staining of wax-embedded and sliced biopsies obtained using 265 
flexible cystoscopy routinely demonstrated intact urothelium of full-thickness in 266 
samples of all three experimental groups of patients (i.e. non-OAB [8 of 8 267 
specimens], OAB without pyuria [11 of 13 specimens], and OAB with pyuria [6 of 6 268 
specimens]) (Figure 1A).  Morphologically distinct umbrella cells were evident on the 269 
luminal side of the urothelium further demonstrating the integrity of the tissue 270 
(Figure 1B).   271 
 272 
Basal ATP release is significantly greater from urothelium of OAB patients with 273 
pyuria. To measure ATP release from microdissected urothelium, we used a luciferin 274 
luciferase assay.  ATP levels became detectable after 15 min and stabilized at 30-40 275 
min (data not shown) and consequently recordings were taken at 60 min.  The subtle 276 
increase in concentration of ATP, which stabilized with time, was taken to represent 277 
basal (i.e. unstimulated) release of ATP.  Basal release of ATP was significantly 278 
greater from urothelium of OAB patients with pyuria (78.1±20.6 nM/5 mg of wet 279 
tissue [hereafter referred to as simply ‘nM’], n=15, P<0.05) than from non-OAB 280 
patients (1.9±1.5 nM, n=9) or OAB patients without pyuria (2.2±1.7 nM, n=33) 281 
(Figure 2A).  Application of a hypotonic solution, to mimic stretch and thus bladder 282 
filling, resulted in substantial, and similar increase in ATP release from the 283 
urothelium of all three experimental groups (non-OAB patients, 129±48 nM, n=9; 284 
OAB patients without pyuria, 38±18 nM, n=33; OAB patients with pyuria, 268±188 285 
nM, n=15) (Figure 2B).  Peak stretch-evoked ATP levels (i.e. the highest 286 
concentration of ATP measured following stimulation) was achieved within 1 min 287 
irrespective of experimental group (n=18; data not shown).  The concentration of 288 
ATP decreased during hypotonic insult suggesting degradation by endogenous tissue 289 
ATPases.  As expected, increasing hypotonicity caused additional ATP release from 290 
urothelium (~2-fold with 25% hypotonic buffer, ~10-fold with 50% hypotonic buffer, 291 
and ~20-fold with 75% hypotonic buffer).  The concentration of ATP released from 292 
urothelium following osmotic insult decreased by 51±8% (n=9) and 52±11% (n=9) 293 
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after 3 min for samples from non-OAB patients and OAB patients with pyuria, 294 
respectively, and levels returned to basal concentrations within 10-12 min in both 295 
cases.  However, for samples from OAB patients without pyuria, the decrease in 296 
concentration of stimulated-ATP release was significantly less after 3 min (26±7%; 297 
n=9; P<0.05) and returned to basal concentrations in ~30 min (Figure 2C).  The 298 
slower rate of stimulated ATP decay seen with urothelium obtained from OAB 299 
patients without pyuria was similar to that with urothelium obtained from non-OAB 300 
patients in the presence of the ATPase inhibitor ARL 67156 (100 μM; n=5) (Figure 301 
2C); ARL 67156 did not alter the peak concentration of stimulation-evoked ATP 302 
release (data not shown).  For ATP concentration measurements following 303 
stimulation, results obtained using HPLC correlated well with results from the 304 
luciferin luciferase assay (data not shown); however it was not possible to use HPLC 305 
to measure basal ATP release as, in some cases, concentrations were below the level 306 
of accurate quantification using the HPLC technique. 307 
 308 
Basal ATP release mechanisms differ from stretch-evoked stimulated release.  We 309 
pharmacologically investigated the molecular mechanism(s) by which ATP is released 310 
(primarily stretch-evoked) from human urothelium obtained from non-OAB patients, 311 
OAB patients without pyuria, and OAB patients with pyuria, using a luciferin 312 
luciferase assay.  Basal ATP release from urothelium of OAB patients with pyuria was 313 
significantly inhibited (by 67±9%, n=3) by the P2 receptor antagonist suramin (1 mM) 314 
and almost abolished by the hemichannel and gap junction blocker carbenoxolone 315 
(CBX, 50μM; n=3), yet, was significantly potentiated (by 74±13%, n=3) by the P2 316 
receptor agonist UTP (1 μM) (Figure 3A).  The UTP-evoked potentiation of ATP was 317 
subtly inhibited (by ~30 nM, n=3) by co-incubation with CBX (50 μM) and 318 
significantly inhibited by co-incubation with suramin (1 mM; P<0.05, n=3), suggesting 319 
at least two mechanisms of ATP release (i.e. hemichannel-mediated and 320 
downstream P2 receptor-evoked) (Figure 3A and 7A).  Botulinum toxin-A (BTX-A; 20 321 
units/ml) known to inhibit vesicular release of ATP, brefeldin-A (BFA; 20 μM) known 322 
to inhibit vesicular trafficking, capsazepine (3 μM) a blocker of stretch-activated TRP 323 
channels, and 4,4'-diisothiocyano-2,2'-stilbenedisulfonic acid (DIDS, 100 μM) a 324 
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calcium-activated chloride channel blocker, did not significantly alter basal ATP 325 
release (all n=3-4) (Figure 3A).  Unfortunately, basal ATP release, as opposed to 326 
stretch-evoked ATP release, from urothelium of non-OAB patients and OAB patients 327 
without pyuria could not be fully investigated due to barely detectable levels of ATP 328 
(see Figure 2A).  However, the effects of UTP (1 μM, n=3) were investigated in these 329 
tissues and found not to significantly increase basal ATP concentration.  Stretch-330 
evoked ATP release (i.e. release evoked by a hypotonic stimulus) from urothelium of 331 
OAB patients with pyuria was significantly inhibited (by 72±14%, n=5) by suramin (1 332 
mM; P<0.05) and almost abolished by BTX-A (20 units/ml, n=3) and BFA (20 μM, 333 
n=3), but unaffected by capsazepine, CBX, DIDS or UTP (n=3-5) (Figure 3B).  334 
Stimulated ATP release from urothelium of non-OAB patients and OAB patients 335 
without pyuria, in addition to being abolished by suramin, BTX-A and BFA, was 336 
significantly inhibited by capsazepine (by 67±11% [n=3] control and 83±8% [n=4] 337 
OAB-pyuria; P<0.05).  338 
Given that BTX-A abolished hypotonicity-evoked ATP release from urothelium 339 
of OAB patients with pyuria (Figure 3B) we investigated whether vesicles were 340 
evident in the urothelium.  Quinacrine staining of wax-embedded and sliced biopsies 341 
demonstrated ATP-containing vesicular structures throughout the urothelium and in 342 
underlying tissue (Figure 4A).  Hypotonic challenge of biopsies from OAB patients 343 
with pyuria prior to wax embedding and slicing resulted in significantly less dense 344 
quinacrine staining (3.9±1.3 arbitary units [AU], n=3, as compared to 0.9±0.3 AU, 345 
n=3), suggesting vesicle emptying following hypotonic stimulation (Figure 4B), which 346 
was inhibited by the addition of BTX-A (1.3±1.3 AU, n=3). 347 
 348 
Altered expression of P2 receptor mRNA in bladder urothelium of OAB patients.  To 349 
quantify the relative abundance of P2 receptor mRNA in microdissected urothelium 350 
of non-OAB patients, OAB patients without pyuria, and OAB patients with pyuria, we 351 
calculated a ratio of the P2 receptor gene of interest to a constitutively expressed 352 
housekeeping gene (GAPDH) using RT-PCR. 353 
We failed to detect significant levels (i.e. >5 arbitrary units) of P2X4 and P2Y4 354 
mRNA in urothelium from any experimental group.  In contrast, significant amounts 355 
 13
of mRNA were detected for P2X1, 2, 3, 5, 6 and 7, and P2Y1, 2, 6, 11, 12, 13, 14 in 356 
urothelium of non-OAB controls; order of expression:P2Y14>>P2X1, 3, 5, 6 and 357 
7=P2Y1, 6, 11, 12 and 13>P2X2=P2Y2 (Figure 5).  Urothelium from OAB patients without 358 
pyuria showed a significant increase in abundance of P2Y11 and 13 mRNA (by 200-fold 359 
and 10-fold, respectively; n=6; P<0.01).  Whereas, urothelium from OAB patients 360 
with pyuria showed a significant increase in abundance of P2Y2 and 11 mRNA (100-fold 361 
and 50-fold, respectively; n=6; P<0.01) (Figure 5B).  362 
 363 
Intracellular bacteria in shed urothelial cells of OAB patients with pyuria.  To 364 
investigate whether intracellular bacteria are responsible for increased basal release 365 
of ATP from urothelium from OAB patients with pyuria we stained cytospun fresh 366 
urine samples with acridine orange and crystal violet.  Biopsy tissue was not used in 367 
this part of the investigation given its precious nature and the necessity of its use in 368 
mechanistic luciferin luciferase studies.  Planktonic bacteria were observed in 1 of 16 369 
samples from non-OAB patients, whereas, intracellular bacteria were not observed 370 
in any sedimentary cells (8±2 urothelial cells per sample, n=16) (Figure 6A).  371 
Similarly, planktonic bacteria were observed in <10% of samples from OAB patients 372 
without pyuria (n=33) and intracellular bacteria were not observed in any 373 
sedimentary cells (Figure 6B).  The number of sedimentary cells identified as 374 
urothelial cells in urine samples from OAB patients without pyuria was 15±3 (n=33).  375 
Planktonic bacteria were observed in 9 of 16 samples from OAB patients with pyuria, 376 
and intracellular bacteria were observed in sedimentary urothelial cells from 13 377 
samples (19±3 urothelial cells per sample, n=16).  In the 13 samples, 52±9% of 378 
urothelial cells were found to contain intracellular bacteria (Figure 6C). To confirm 379 
that the cells containing intracellular bacteria were urothelial cells, the deposit was 380 
fixed with PFA (4%) then further treated with anti-Uroplakin III (UP-III) and DAPI.  In 381 
all cases, those cells initially identified as urothelial cells by their morphology alone, 382 
were confirmed as urothelial cells by positive UP-III immunofluorescence.  Z-stack 383 
images obtained by confocal microscopy further confirmed the intracellular 384 
localization of bacteria (Figure 6D). 385 
 386 
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Urinary AMP and adenosine levels are elevated in OAB.  Given that basal ATP release 387 
is significantly greater from urothelium of OAB patients with pyuria we investigated 388 
whether this was detectable by HPLC in MSU samples, as well as other nucleotides 389 
(ADP, AMP, GTP, GDP, GMP, UTP, UDP and UMP) and nucleosides (adenosine, 390 
guanosine and uridine) that may be altered (Table 1).  Urinary AMP levels were 391 
significantly greater in samples from OAB patients without pyuria (14.4±8.3 μM, 392 
n=17, P<0.05) and OAB patients with pyuria (8.5±2.3 μM, n=16, P<0.05) than non-393 
OAB patients (2.7±0.5 μM, n=11).  In addition, urinary adenosine levels were 394 
significantly greater in samples from OAB patients without pyuria (228±106 μM, 395 
n=17, P<0.05) than non-OAB patients (61±58 μM, n=11).  Nucleotide and nucleoside 396 
release from biopsy tissue was not investigated using HPLC given the necessity of the 397 
tissue’s use in mechanistic luciferin luciferase studies.  398 
 399 
400 
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Discussion: 401 
The main findings of this investigation revealed that basal release of ATP from the 402 
urothelium is significantly greater for human OAB patients with pyuria ≥10 wbc μl-1 403 
than for OAB patients without pyuria (or with pyuria <10 wbc μl-1) or non-OAB 404 
patients, which may account for the heightened symptoms seen in these patients 405 
(36).  More specifically, we present evidence that (1.) bacteria reside in some 406 
urothelial cells of OAB patients with pyuria ≥10 wbc μl-1, and (2.) a sequential 407 
signaling mechanism occurs whereby (i) basal ATP release from the urothelium is via 408 
hemichannels, (ii) ATP released through hemichannels acts in an autocrine/paracrine 409 
manner by activating P2 receptors expressed throughout the urothelium (likely to be 410 
the P2Y2 subtype, shown here to be upregulated in OAB patients with pyuria), and 411 
(iii) P2 receptor activation causes yet further ATP release from the urothelium via an 412 
undetermined mechanism.  Taken together, these findings lead to the proposal that 413 
in a subset of OAB patients (i.e. OAB patients presenting with pyuria ≥10 wbc μl-1), 414 
there is heightened basal ATP release from, and increased P2 receptor expression in, 415 
the urothelium originating from intracellular bacteria colonization, that culminates in 416 
inappropriate sensory nerve excitation and the symptoms of OAB seen in these 417 
patients (see Figure 7A). 418 
 In addition to reporting altered urothelial ATP release from OAB patients 419 
presenting with pyuria, we also describe stretch-evoked ATP signaling in human 420 
urothelium (which does not significantly differ between OAB patients without 421 
pyuria, OAB patients with pyuria, and non-OAB patients).  Specifically we present 422 
evidence that a sequential signaling mechanism occurs whereby (i) urothelial cell 423 
stretch (as occurs in bladder filling) evokes vesicular ATP release, (ii) ATP released 424 
from vesicles acts in an autocrine/paracrine manner by activating P2 receptors (of 425 
which a variety and abundance are expressed throughout the urothelium), and (iii) 426 
P2 receptor activation causes yet further vesicular ATP release from the urothelium 427 
to presumably activate P2X receptors on suburothelial sensory nerves and therefore 428 
signal bladder fullness (see Figure 7B). 429 
 430 
Mechanisms of urothelial ATP release. 431 
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It is well established that extracellular nucleotide signaling arising from the 432 
urothelium is important in the regulation of bladder function (3, 8).  However, to 433 
date little work has been performed on human urothelium. This, in part, is because 434 
of the reported fragility of the urothelial cell layer and superficial umbrella cells, and, 435 
the logistic difficulty in obtaining tissue samples using the cold-cup biopsy technique 436 
(normally performed under general anaesthesia).  However, here we demonstrate 437 
that full-thickness intact urothelium obtained using flexible cystoscopy, a routinely 438 
used procedure using a fibre optic instrument and not requiring general anesthesia 439 
of the donor, can be used successfully to study the physiology/pathophysiology of 440 
the urothelium in vitro. 441 
 Using urothelium samples, obtained by flexible cystoscopy, we have 442 
presented evidence for an autocrine/paracrine ATP signaling mechanism in human 443 
urothelium that presumably culminates in sensory nerve excitation (see Figure 7).  444 
Our proposed mechanisms of autocrine/paracrine ATP signaling are broadly in 445 
keeping with others.  Autocrine/paracrine signaling by ATP, and other nucleotides, in 446 
epithelial tissues is a well documented phenomenon, especially in renal tissue where 447 
basal ATP release and stretch-evoked ATP release (a function of tubular flow rate) 448 
influence ion and water transport mechanisms, and may even influence intrarenal 449 
blood flow (21, 35, 39, 60).  With respect to the bladder, the group of Birder was the 450 
first to propose that the abundance, and variety, of P2 receptors expressed 451 
throughout the urothelial cell layer might serve to amplify stretch-evoked ATP 452 
signaling (15).  Non-neuronal cellular release mechanisms of ATP are not well 453 
understood.  Proposals to date involve a number of complementary pathways that 454 
include transport via ATP-binding-cassette (ABC) proteins, connexin hemichannels, 455 
large-diameter anion channels and exocytotic vesicular release (1, 31).  Our data 456 
using human urothelium demonstrate ATP release via hemichannels and vesicles 457 
(see Figure 3 and 4).  This investigation extends findings of earlier studies using 458 
urothelium by demonstrating multiple, and different, release mechanisms for both 459 
basal release (in OAB patients with pyuria) and stretch-evoked release (from all 460 
experimental groups).  However, disappointingly we report at least one unidentified 461 
ATP release mechanism in OAB patients with pyuria that is insensitive to all 462 
blockers/antagonists tried (see Figure 7).  It is perhaps prudent to mention at this 463 
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juncture that the effect of bacteria on urothelial cell permeability has not be 464 
investigated, which of course may also account for increased increased basal release 465 
of ATP from the urothelium of patients with OAB and pyuria.  466 
Current OAB therapies include antimuscarinic and/or BTX-A treatment.  The 467 
former is associated with severe side-effects and high rates of withdrawal, and the 468 
latter is notoriously expensive. Our study tested the ability of suramin and BTX-A to 469 
alter the ATP signaling cascades seen in urothelium from OAB patients.  Suramin, 470 
successfully inhibited the exaggerated basal ATP release unique to OAB patients with 471 
pyuria, whereas BTX-A was without effect (see Figure 3A).  However, stimulated ATP 472 
release, similar in non-OAB patients and OAB patients alike, was inhibited by both 473 
suramin and BTX-A (see Figure 3B).  These findings suggest that BTX-A may not be a 474 
suitable therapy for those suffering from OAB with pyuria, and that selective 475 
targeting of urothelial ATP receptors may be an alternative pharmacological strategy 476 
to currently used antimuscarinics in the treatment of OAB (irrespective of pyuria 477 
status). 478 
 479 
P2 receptor expression in urothelium. 480 
Using real time-PCR, we molecularly characterized the P2 receptor subtypes 481 
expressed in urothelium of non-OAB patients, OAB patients without pyuria, and OAB 482 
patients with pyuria. We consistently demonstrated mRNA expression of P2X1-3 and 483 
5-7 receptor subunits, but not P2X4, in samples from all 3 experimental groups.  The 484 
level of expression for each subtype did not significantly differ between 485 
experimental groups.  Given the ability of P2X receptors to form homomeric and 486 
heteromeric ion channels, the possibility exists that up to 10 subtypes of P2X 487 
receptor (P2X1, 2, 3, 5, 6, 7, 1/2, 1/5, 2/3 and 2/6) may be functionally expressed in 488 
human urothelium.  For P2Y receptors, we consistently demonstrated mRNA 489 
expression for all subtypes (P2Y1, 2, 6 and 11-14) with the exception of P2Y4.  However, 490 
levels of P2Y2, 11 and 13 were significantly increased in OAB patients, with an increase in 491 
P2Y2 being specific to OAB patients with pyuria and P2Y13 being specific to OAB 492 
patients without pyuria (see Figure 5). 493 
Our PCR findings demonstrating expression of almost all P2 receptors in 494 
human urothelium are broadly in accordance with previous studies that collectively 495 
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reported all P2X (P2X1-7) and P2Y1, 2, 4, 6 and 11 localization/expression in native 496 
urothelium of human, rat, mouse, rabbit, guinea-pig and cat and in a human 497 
urothelial cell line (UROtsa cells) (4, 6, 13-15, 18, 19, 24, 40, 42, 50, 57, 61). That 498 
others have not demonstrated P2Y12-14 expression is perhaps due to the recent 499 
discovery and cloning of these subtypes from human tissue.  Our PCR investigation 500 
also extends findings of earlier studies in which P2 receptor expression in the 501 
urothelium is described for both human and feline IC patients, whereby P2X1 and 3 502 
and P2Y2 are decreased (6, 15). 503 
Interestingly, stimulation of some P2 receptors (P2X2, 4 and 7, and P2Y6) 504 
results in the release of key proinflammatory cytokines (e.g. IL-1ß, IL-6, IL-8 and 505 
TNFα) (3, 47). IL-1, IL-6 and IL-8 have been shown to presage UTI symptoms (27, 53). 506 
Here we present data suggesting that P2Y6 expression may be increased (not quite 507 
significant; Figure 5B) in the urothelium of OAB patients with pyuria, which may be 508 
critical to the release of these cytokines, and amplify the cascade of events leading 509 
to the heightened symptoms of OAB.  510 
 511 
Bacterial colonization of bladder urothelium. 512 
With our findings in mind, the most apposite series of animal experiments have been 513 
reported by the Hultgren group (41, 59). Using a murine model of chronic urinary 514 
infection, they demonstrated the ability of E. coli to colonize the superficial 515 
urothelium forming intracellular bacterial colonies (IBCs). These colonies exhibit a 516 
reduced susceptibility to antibiotics and host immune mechanisms. Electron 517 
microscopy studies showed that colonies formed pod-like protrusions from the cell 518 
wall, with the resident bacteria encased in a polysaccharide-rich matrix surrounded 519 
by a protective shell. Eventually, bacteria detached from the pod and burst into the 520 
bladder lumen where the escaped bacteria then infected fresh cells.  However, in 521 
this study we failed to identify bacteria residing within the urothelial cells lining the 522 
bladder (i.e. in biopsy material) but instead bacteria were identified inside shed 523 
urothelial cells found in urine samples. The possibility exists that the shed umbrella 524 
cells were from the renal pelvis, ureters, urethra and bladder; although unlikely 525 
given that the urine was obtained by CSU sampling.    526 
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Interestingly, Rosen and colleagues have published data that showed IBCs 527 
forming in urothelial cells of patients with acute cystitis (60). UPEC 528 
lipopolysaccharide (LPS) is an extremely potent activator of innate immune 529 
responses acting via binding to CD14 and Toll like receptors in the bladder 530 
urothelium to activate p38 MAP kinase, Ca2+ and cAMP signalling which in turn 531 
triggers IL-6 and IL-8 production. (34, 56). Furthermore, ATP released from both 532 
UPEC and infected cells can situmlate IL-8 production via P2 receptor signalling (4, 533 
43, 55). IL-6 is associated with activation of the acute phase response, which 534 
increases production of C-reactive protein from the liver and IL-8 acts as a 535 
chemotactic factor for neutrophils (pyuria).  The presence of pyuria in the absence of 536 
infection (determined by failure to isolate ≥105colony forming units) in a subset of 537 
OAB patients, which suggests bladder infection and IBC, is a relatively recent 538 
discovery (44).    539 
 540 
Urinary nucleotides and nucleosides as biomarkers of OAB. 541 
Previous studies have utilized the luciferin luciferase assay to investigate the 542 
potential for urinary ATP concentration to serve as a suitable biomarker for UTIs.  543 
These studies report ATP concentrations of 5-25 nM in MSU samples collected from 544 
patients testing negative for UTIs, and 112-140 nM for patients with positive culture 545 
(26, 38), suggesting that ATP could be a biomarker for urinary infection.  However, a 546 
more recent study looking at ATP concentrations in the urine of OAB patients found 547 
similar low levels of ATP in both OAB and non-OAB control groups (1.5 and 1.4 nM 548 
[normalized to creatinine concentrations], respectively) (33). Using a novel HPLC 549 
technique we found significantly higher levels of AMP in MSU samples from OAB 550 
patients (irrespective of pyuric status) than in samples from non-OAB patients.  In 551 
addition, we detected elevated adenosine in OAB patients without pyuria.  Whereas 552 
these data are currently too preliminary to propose biomarkers for OAB, it may be 553 
useful in determining additional signaling mechanisms responsible for the symptoms 554 
of OAB.  555 
 556 
Should pyuria inform the diagnosis and treatment of OAB?  557 
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Data presented here raise the question as to whether OAB with pyuria should be 558 
classified and treated differently to OAB without pyuria.  Considerable overlap 559 
already exists between OAB and chronic prostatitis or “chronic pelvic pain 560 
syndrome” and IC, also called “painful bladder syndrome”, and in all cases the 561 
diagnosis, rightly or wrongly, relies on exclusion of urinary infection by routine 562 
culture methods (54).  Our findings suggest that OAB with pyuria has a subclinical 563 
UTI component (intracellular bacteria in the urothelium), not dissimilar to recent 564 
findings for IC yet without pain and inflammation (29). That significant basal ATP 565 
release is novel to OAB with pyuria suggests treatment could be designed 566 
accordingly.  Further multi-centre investigations are required to fully answer this 567 
question; which may need to wait until routine UTI detection methodologies are 568 
updated. 569 
 570 
Summary: 571 
These data provide a better understanding of OAB aetiology and, nucleotide release 572 
and signaling in bladder epithelium (in health and disease).  The former may prompt 573 
clinical re-classification of OAB, to aid successful diagnosis and treatment in the 574 
future.  The later may help identify alternative, efficacious, and acceptable 575 
therapeutic treatments for the unpleasant symptoms of OAB.  Conceivably, efficient 576 
therapeutic strategies may be evolved to target nucleotide signaling by intravesicular 577 
delivery methods to alleviate OAB symptoms and/or treat intracellular bacteria of 578 
OAB with pyuria. 579 
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Figure 1.  Bladder biopsies obtained using flexible cystoscopy have full-thickness 596 
urothelium.  Human bladder biopsies were obtained using a flexible cystoscope 597 
under local or general anaesthetic.  Biopsies were placed in 10% formalin for 48 h 598 
prior to dehydration with alcohol and xylene, and parrafin wax embedding.  Sections 599 
(6 μm thick) were stained with H&E to investigate urothelium integrity.  (A) 600 
Representative microphotograph of a biopsy section from an OAB patient that 601 
presented with pyuria of <10 wbc μl-1.  Full-thickness urothelium is evident in the 602 
sample (between arrowheads).  (B) Representative microphotograph of a biopsy 603 
section from an OAB patient that presented with pyuria of ≥10 wbc μl-1.  Full-604 
thickness urothelium is evident in the sample (as in A); umbrella cells lining the 605 
luminal membrane are clearly visible (arrowheads).  Scale bars equal 200 μm. 606 
 607 
Figure 2. Greater ATP release from urothelium of OAB patients with pyuria of ≥10 608 
wbc μl-1.  ATP release from microdissected urothelium was measured using a 609 
luciferin luciferase asssay.  ATP release was first measured at rest (classified here as 610 
‘basal’ release) and then after addition of a hypotonic solution (to cause cell stretch 611 
and mimic bladder filling; classified here as ‘stimulated’ release).  Data for stimulated 612 
ATP release is presented following subtraction of basal release values.  (A) Basal ATP 613 
release from urothelium of OAB patients with pyuria ≥10 wbc μl-1 (OAB + pyuria; 614 
n=15) was significantly greater than basal ATP release from urothelium of OAB 615 
patients without pyuria, or with pyuria <10 wbc μl-1 (OAB - pyuria; n=9), or non-OAB 616 
patients (P<0.05; n=9).  (B) Stimulated ATP release from the urothelium was not 617 
significantly different between experimental groups (non-OAB patients, n=9; OAB 618 
patients without pyuria, n=9; OAB patients with pyuria, n=15).  (C) The rate at which 619 
the concentration of ATP decreased, following stimulation and in the continued 620 
presence of hypotonic solution, was greatest from urothelium of non-OAB patients 621 
(n=9) and OAB patients with pyuria (n=15).  The decreased rate of stimulated ATP 622 
degradation seen from urothelium of OAB patients without pyuria (n=9), was similar 623 
to that from urothelium of non-OAB patients in the presence of the ATPase inhibitor 624 
ARL 67156 (100 μM, n=5).  Data shown are mean±SEM. * denotes significant 625 
difference from non-OAB, where P<0.05. 626 
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Figure 3. Mechanisms of ATP release from urothelium of OAB patients with pyuria.  628 
ATP release from microdissected urothelium of OAB patients with pyuria ≥10 wbc μl-629 
1 (OAB + pyuria) was measured using a luciferin luciferase asssay.  ATP release was 630 
first measured at rest (‘basal’) or after addition of a hypotonic solution (‘stimulated’).  631 
Data for stimulated ATP release is represented following subtraction of basal release 632 
values.  Urothelium was pre-treated with the stated drug for 5 min prior to 633 
measuring ATP release (basal or stimulated).  (A) Basal ATP release from urothelium 634 
was significantly attenuated by both suramin (1 mM, n=3) and carbenoxolone (CBX, 635 
50 μM, n=3), and significantly potentiated by UTP (1 μM, n=3) (P<0.05 in all cases).  636 
The potentiating effects of UTP were inhibited by co-treatment with either CBX or 637 
suramin.  (B) Stimulated ATP release from the urothelium was significantly 638 
attenuated by suramin (n=5), botulinum toxin-A (BTX-A, 20 units/ml, n=3) or 639 
brefeldin-A (BFA, 20 μM, n=3) (P<0.05 in all cases).  Co-treatment of either BFA or 640 
suramin with UTP (n=3 in both cases) had no further effect.  Data shown are 641 
mean±SEM. * denotes P<0.05. 642 
 643 
Figure 4.  Urothelial cell stretch evokes vesicular release of ATP.  Human bladder 644 
biopsies were obtained using a flexible cystoscope under local anaesthetic.  Biopsies 645 
were placed in 10% formalin for 48 h prior to dehydration with alcohol and xylene, 646 
and parrafin wax embedding.  In some cases, biopsies were challenged with a 647 
hypotonic solution (to cause cell stretch and mimic bladder filling) prior to fixation.  648 
Sections (6 μm thick) were stained with DAPI and quinacrine to investigate 649 
localisation of ATP-containing vesicles.  (A) Representative microphotograph of a 650 
biopsy section from an OAB patient with pyuria ≥10 wbc μl-1;  i) DAPI staining (blue), 651 
ii) quinacrine staining (green), iii) composite image of DAPI and quinacrine staining, 652 
iv) bright field image.  ATP containing vesicles are evident throughout the 653 
urothelium.  (B) Representative microphotograph of a biopsy section from an OAB 654 
patient with pyuria ≥10 wbc μl-1, challenged with a hypotonic solution prior to 655 
fixation,;  i) - iv) as in A.  ATP containing vesicles are less evident throughout the 656 
urothelium.  Scale bars equal 100 μm. 657 
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Figure 5.  Altered P2Y receptor expression in urothelium of OAB patients. RT-PCR was 659 
performed on microdissected urothelium of non-OAB patients, OAB patients without 660 
pyuria, or with pyuria <10 wbc μl-1 (OAB – pyuria), and OAB patients with pyuria ≥10 661 
wbc μl-1 (OAB + pyuria).  The ratio of the P2 receptor gene of interest to a 662 
constitutively expressed housekeeping gene (GAPDH) was calculated. (A) Ionotropic 663 
P2X receptor mRNA levels were similar in urothelium from the three experimental 664 
groups (n=6).  (B) Urothelium from OAB patients without pyuria showed a significant 665 
increase in abundance of metabotropic P2Y11 and 13 mRNA (n=6; P<0.01).  Whereas, 666 
urothelium from OAB patients with pyuria showed a significant increase in 667 
abundance of metabotropic P2Y2 and 11 mRNA (n=6; P<0.01). Data shown are 668 
mean±SEM. * denotes significant difference from non-OAB, where P<0.01. 669 
 670 
Figure 6.  Intracellular bacteria identified in shed urothelial cells from OAB patients 671 
with pyuria ≥10 wbc μl-1. Fresh urine was spun onto slides using a cytospin and the 672 
deposit stained with acridine orange (which fluoresces green in the presence of 673 
viable organism DNA).  In order to differentiate extracellular from intracellular 674 
bacteria, a crystal violet counter-stain was added to quench the fluorescence of 675 
extracellular microorganisms.  Images were acquired using an upright fluorescence 676 
microscope.  Intracellular bacteria were not observed in sedimentary cells from the 677 
urine of non-OAB patients (see A for a representative image) or OAB patients 678 
without pyuria, or with pyuria <10 wbc μl-1 (OAB – pyuria; see B for a representative 679 
image).  (C) Representative microphotograph of shed urothelial cell colonized by 680 
intracellular bacteria (arrow) from an OAB patient with pyuria ≥10 wbc μl-1 (OAB + 681 
pyuria).  Bacterial colonization of urothelial  cells was seen in 81% of urine samples 682 
tested (n=16), and of those, 52±9% of urothelial cells contained bacteria (19±3 683 
urothelial cells per sample).  Further confirmation of the intracellular localisation of 684 
bacteria and cell type was obtained by treatment with anti-uroplakin III (red; a 685 
marker of urothelial cells) and DAPI (blue; marker of DNA).  Images were acquired 686 
with a confocal microscope and Z-series processed using Volocity software.  (D) 687 
Representative 2D microphotograph of three shed urothelial cells from urine of an 688 
OAB patient with pyuria (Di), whereby the intracellular localisation of bacteria is 689 
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evident in the side projections (Dii and Diii; dashed line shows origin of side-690 
projection).  Scale bars equal 10 μm. 691 
 692 
Figure 7.  Proposed mechanisms of ATP release from urothelium of OAB patients with 693 
pyuria.  In our investigations, basal release of ATP was ~15-fold greater from 694 
urothelium of OAB patients with pyuria, nearing levels normally associated with 695 
stretch and bladder fullness.  Histology demonstrates that bacteria reside in 696 
urothelial cells, and RT-PCR suggest that levels of P2Y2 and P2Y11 are increased. (A) 697 
When the bladder is at rest there is a substantial release of ATP (basal release) from 698 
the urothelium, which in our experiments is abolished by CBX, suggesting release via 699 
hemichannels (1.).  We propose that the released ATP acts in a paracrine/autocrine 700 
fashion to activate P2 receptors expressed throughout the urothelium (including the 701 
upregulated P2Y2 and P2Y11 subtypes) (2.).  P2 receptor activation in turn evokes 702 
further ATP release (in our experiments attenuated by suramin and potentiated by 703 
UTP) via an undetermined mechanism (3.).  Presumably, released ATP reaches levels 704 
able to activate P2 receptors expressed on suburothelial sensory nerves, resulting in 705 
inappropriate signalling normally associated with bladder fullness (4.).  We 706 
hypothesise that the presence of intracellular bacteria (IB) is responsible for 707 
increased P2 receptor expression and hemichannel mediated ATP release.  (B) When 708 
the urothelium is stretched (i.e. when the bladder is full) there is a substantial 709 
release of ATP (stimulated release), which in our experiments is abolished by BTX-A 710 
or BFA, suggesting release from vesicles (1.).  We propose that the released ATP acts 711 
in a paracrine/autocrine fashion to activate P2 receptors expressed throughout the 712 
urothelium (2.).  P2 receptor activation in turn evokes further ATP release (in our 713 
experiments attenuated by suramin) again from vesicles (3.).  Presumably, released 714 
ATP reaches levels able to activate P2 receptors expressed on suburothelial sensory 715 
nerves, resulting in signalling of bladder fullness (4.).  The presence of intracellular 716 
bacteria (IB) does not appear to alter stimulated ATP release from urothelium. 717 
 718 
 719 
 720 
 721 
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Table 1: 722 
Compound Non-OAB 
OAB 
without pyuria 
OAB
with pyuria 
ATP 1.4±0.8 nM 4.2±3.6 nM 2.0±0.8 nM 
ADP 19.0±8.5μM 11.7±2.5μM 24.2±6.5 μM 
AMP 2.7±0.5μM 14.4±8.3 μM* 8.5±2.2 μM* 
adenosine 61.0±58.5μM 228±86 μM* 113±42.3 μM 
GTP 44.9±13.9 μM 157±92.7μM 89.8±42.3 μM 
GDP 128±54.0 μM 83.2±20.0 μM 138±47.3 μM 
GMP 5.5±2.0μM 20.7±10.3 μM 15.9±6.7 μM 
guanosine 478±174 μM 225±81.5μM 527±176 μM 
UTP 9.9±2.4 μM 22.9±14.5 μM 8.6±2.6 μM 
UDP 30.6±13.9μM 20.2±6.3μM 46.5±19.3 μM 
UMP 1.4±0.6 mM 734±393 μM 667± 261 μM 
uridine 7.3±3.4μM  25.0±8.1 μM 10.0±4.8 μM 
 723 
Urinary AMP levels are elevated in OAB patients presenting with pyuria.  HPLC was 724 
used to measure the concentration of nucleotides and nucleosides in urine samples 725 
from non-OAB patients, OAB patients without pyuria or with pyuria <10 wbc μl-1 726 
(OAB without pyuria), or with pyuria≥10 wbc μl-1 (OAB with pyuria). Creatinine levels 727 
were similar in all 3 patient groups (non-OAB, 119±25 mg/dl; OAB without pyuria, 728 
132±20 mg/dl; OAB with pyuria, 121±14 mg/dl).  Data are mean±SEM (n=11 for non-729 
OAB, n=16 for OAB without pyuria, n=17 for OAB with pyuria).  * denotes statistical 730 
difference from non-OAB patients (P<0.05). 731 
732 
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Appendix: 733 
Human P2 receptor primers and mRNA accession numbers.  Primers were designed 734 
using Primer 3 Web software (Whitehead Institute for Biomedical Research, 735 
Cambridge, USA) and manufactured by Eurofins-MWG (Ebersberg, Germany). 736 
Gene Accession No. 5’to 3’ Sequence Position 
P2X1 NM_002558 S: CGCCTTCCTCTTCGAGTATGA
AS: AGATAACGCCCACCTTCTTATTAC 
471-491 
538 – 514 
P2X2 NM_170682 S: GCCTACGGGATCCGCATT
AS: TGGTGGGAATCAGGCTGAAC 
958 – 975 
1024– 1005 
P2X3 NM_002559 S: GCTGGACCATCGGGATCA
AS: GAAAACCCACCCTACAAAGTAGGA 
135 – 152 
205 – 182 
P2X4 NM_002560 S: CCTCTGCTTGCCCAGGTACTC
AS: CCAGGAGATACGTTGTGCTCAA 
1108– 1128 
1176– 1155 
P2X5 NM_002561 S: CTGCCTGTCGCTGTTCGA
AS: GCAGGCCCACCTTCTTGTT 
311 – 328 
378 – 360 
P2X6 AF065385 S: AGGCCAGTGTGTGGTGTTCA
AS: TCTCCACTGGGCACCAACTC 
488 – 507 
555 – 536 
P2X7 NM_002562 S: TCTTCGTGATGACAAACTTTCTCAA
AS: GTCCTGCGGGTGGGATACT 
401 – 425 
476 – 458 
P2Y1 NM_002563 S: CGTGCTGGTGTGGCTCATT
AS: GGACCCCGGTACCTGAGTAGA 
1352 – 1370 
1419 – 1399 
P2Y2 NM_176072 S:GAACTGACATGCAGAGGATAGAAGAT
AS: GCCGGCGTGGACTCTGT 
1495 – 1520 
1567 – 1551 
P2Y4 NM_002565 S: CCGTCCTGTGCCATGACA
AS: TGACCGCCGAGCTGAAGT 
725 – 742 
793 – 776 
P2Y6 NM_176797 S: GCCGGCGACCACATGA
AS: GACCCTGCCTCTGCCATTT 
1171 – 1186 
1227 – 1209 
P2Y11 NM_002566 S: CTGGAGCGCTTCCTCTTCAC
AS: GGTAGCGGTTGAGGCTGATG 
511 – 530 
586 – 567 
P2Y12 NM_022788 S: AGGTCCTCTTCCCACTGCTCTA
AS: CATCGCCAGGCCATTTGT 
318 – 339 
385 – 368 
P2Y13 NM_023914 S: GAGACACTCGGATAGTACAGCTGGTA
AS: GCAGGATGCCGGTCAAGA 
223 – 248 
291 – 274 
P2Y14 NM_014879 S: TTCCTTTCAAGATCCTTGGTGACT
AS: GCAGAGACCCTGCACACAAA 
433 – 456 
505 – 486 
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